Expert Advice for Self-Advocacy

- You are your own best advocate. **Speak up** about what is important to you.
- Communicate your **goals**, including treatment goals.
- Consider a **second opinion** with a CLL specialist.

**Could It Be Time to Treat CLL? Physicians Consider:**

- Low blood counts
- Bulky or symptomatic lymph nodes
- Spleen enlargement or symptoms
- Constitutional symptoms, including:
  - Unintentional weight loss
  - Fatigue
  - Fevers
  - Night sweats
  - Autoimmune cytopenias

**Glossary Terms**

**Evusheld** (tixagevimab co-packaged with cilgavimab): Received emergency use authorization from the Food and Drug Administration (FDA) for use in people with moderate to severe immune compromise who may not have an adequate immune response to COVID-19, vaccination, or have a history of severe adverse reaction to a COVID-19 vaccine or vaccine ingredients.

**Refractory**: A disease or condition that does not respond to treatment.

**Relapse**: The return of a disease or the signs and symptoms of a disease after a period of improvement.

**Shared Decision-Making (SDM)**: Process of communication by which patients and clinicians collaborate to make healthcare decisions. The process encourages patients to take a more active role in their care and treatment.

**Watch and Wait (W&W)**: The period of time before treatment begins in which a patient is monitored for disease progression and symptoms.

**CLL Resources**

- AceCancer: [acecancer.com](http://acecancer.com)
- CancerGRACE: [cancergrace.org](http://cancergrace.org)
- Cancer Support Community: [cancersupportcommunity.org](http://cancersupportcommunity.org)
- CLL Society: [cllsociety.org](http://cllsociety.org)
- The Leukemia & Lymphoma Society: [LLS.org](http://LLS.org)
- Leukemia Research Foundation: [allbloodcancers.org](http://allbloodcancers.org)

**MORE TOOLS FOR EMPOWERMENT**

- Digitally Empowered™
- PEN-Powered Activity Guide
- Empowered Blog
- Empowered! Podcast

Thrive CLL is brought to you by the Patient Empowerment Network. Funding is provided by an unrestricted educational grant from Pharmacyclics, an AbbVie Company, and Janssen Biotech, Inc.

question@powerfulpatients.org

@power4patients

PowerfulPatients.org